When Canada’s billionaire Weston family struck an $8.9 billion (£6.7 billion) deal this week to buy legendary British chemist Boots, most headlines focused on high-street shopping, drugstore rivalries, and the sheer scale of the retail takeover.
Behind closed boardroom doors in Toronto, London, and New York, though, another story caught the financial world off guard: Canadian Imperial Bank of Commerce (CIBC) emerged as a key advisor and lead debt arranger on the transaction.
In doing so, Canada’s fifth-largest lender pulled off the largest leveraged buyout (LBO) financing package in its 159-year history—proving it can go toe-to-toe with global syndicates on transatlantic mega-deals.
Shedding the Cautious Reputation
For decades, the pecking order among Canada’s Big Five banks was clear. While Royal Bank of Canada (RBC) spent billions building out premier investment banking and leveraged finance operations in Manhattan and the City of London, CIBC was largely viewed as a cautious domestic retail lender, happiest handling Canadian mortgages and resource-sector loans.
This Boots mandate turns that perception upside down.
Over the past five years, CIBC has quietly executed a focused strategy: stop trying to be everything to everyone like JPMorgan or Goldman Sachs, and instead follow Canada’s deepest-pocketed family offices, pension funds, and institutional powerhouses wherever they deploy capital around the globe.
Few clients carry more clout than the Westons.
Through their private vehicle Wittington Investments, the family sits atop a retail empire that includes Loblaw and Shoppers Drug Mart. CIBC has spent generations acting as a trusted banker to the dynasty. When Wittington teamed up with Prem Watsa’s Fairfax Financial Holdings to mount a serious bid for Boots, CIBC stepped forward to underwrite the debt alongside Wall Street heavyweights like Morgan Stanley.
Why Bankers Weren’t Afraid of the Debt
Writing multi-billion-dollar underwriting commitments in an era of elevated interest rates is not for the faint of heart. If institutional investors balk at taking the debt off the bank’s books during syndication, the lenders get stuck holding the bag—a risk that has burned Wall Street desks on several high-profile buyouts over recent years.
Boots, however, comes with the kind of financial profile that credit committees dream about.
Unlike trendy fashion chains or discretionary retailers that crash during a downturn, the 177-year-old British chemist is an essential utility of daily life. Over 85% of the UK population lives within a 10-minute walk or drive of a Boots storefront. Between lucrative National Health Service prescription dispensations, an expanding roster of in-store primary health services, and the cash-generating powerhouse of its No7 beauty brand, the company produces remarkably predictable cash flows.
That steady revenue stream makes the debt much easier to package and sell into private credit funds, European institutional investors, and loan syndicates looking for defensive assets.
For CIBC, the upside is huge. Landing the lead spot on a deal this size means pocketing massive underwriting and advisory fees, locking in foreign-exchange hedging business, and proving to institutional clients that Bay Street can fund their most ambitious international acquisitions without having to hand the driver’s seat over to New York.
A New Era for Canadian Capital
The Boots deal signals an important shift in how Canadian lenders play the global game. Armed with strong balance sheets and conservative capital reserves, Canadian banks are using their financial stability to muscle into big-ticket buyout financing when opportunities align with their premier relationships.
As the Boots takeover moves toward its expected close in early 2027, CIBC’s leveraged finance desk has set a new high-water mark. The message to rival dealmakers is hard to miss: when Canadian business royalty decides to make a multi-billion-dollar splash on the other side of the Atlantic, they don't need Wall Street to write the check anymore.
